Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pharmacyclics Inc PCYC

Healthcare Biotechnology

Recent & Breaking News (NDAQ:PCYC)

Goldman Sachs Talks Pfizer's Acquisition Deal Of Medivation

Benzinga.com  August 22, 2016

Ibrutinib (IMBRUVICA®) Phase Ib/II Data Show Promise in Patients with Chronic Graft-Versus-Host-Disease

PR Newswire May 31, 2015

Phase III HELIOS Study Results Show Ibrutinib (IMBRUVICA®) Combination Therapy Significantly Increased Progression-Free Survival in Previously-Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients

PR Newswire May 30, 2015

Ibrutinib (IMBRUVICA®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Study Commences for Patients with Two Relapsed/Refractory Blood Cancers

PR Newswire May 28, 2015

European Medicines Agency Issues Positive Opinion, Recommends Full Approval of IMBRUVICA® (ibrutinib) to Treat Waldenstrom's Macroglobulinemia

PR Newswire May 22, 2015

New ibrutinib (IMBRUVICA®) Data to be Showcased at American Society of Clinical Oncology (ASCO) Annual Meeting

PR Newswire May 13, 2015

Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates

PR Newswire May 1, 2015

New Longer-Term IMBRUVICA® (ibrutinib) Data Show High Response Rates in Patients with Waldenstrom's Macroglobulinemia

PR Newswire April 9, 2015

Solid Tumor Study Investigating Ibrutinib (IMBRUVICA®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Commences in Patients with Relapsed/Refractory Non-Small Cell Lung, Breast and Pancreatic Cancers

PR Newswire April 1, 2015

New ibrutinib (IMBRUVICA®) Data to be Presented at American Association for Cancer Research (AACR) Meeting

PR Newswire March 19, 2015

PHARMACYCLICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

Business Wire March 18, 2015

Independent Data Monitoring Committee Unanimously Recommends Unblinding of IMBRUVICA® (ibrutinib) Phase III Combination HELIOS Trial Based on Interim Analysis Showing Significant Improvement in Progression-Free Survival in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PR Newswire March 16, 2015

Pharmacyclics Inc. Stockholders Encouraged to Contact Securities Law Firm about Takeover

PR Newswire March 10, 2015

PHARMACYCLICS INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to AbbVie

Business Wire March 9, 2015

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Pharmacyclics Inc. of Commencement of Class Action Investigation Concerning the Fairness of the Sale of the Company to AbbVie

Business Wire March 9, 2015

Ryan & Maniskas, LLP Announces Investigation of Pharmacyclics Inc.

PR Newswire March 9, 2015

SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Pharmacyclics, Inc. - PCYC

PR Newswire March 6, 2015

Harwood Feffer LLP Announces Investigation of Pharmacyclics, Inc.

PR Newswire March 5, 2015

Pharmacyclics, Inc. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

PR Newswire March 5, 2015

EQUITY ALERT: The Rosen Law Firm Announces Investigation of Pharmacyclics Inc. Concerning its Proposed Sale to AbbVie Inc. - PCYC

Business Wire March 5, 2015